Wolcott-Rallison syndrome

Wolcott-Rallison syndrome (WRS) is an extremely rare autosomal recessive disorder characterized by the earliest known onset of permanent neonatal diabetes mellitus, typically presenting in the first six months of life. It is caused by mutations in the EIF2AK3 gene (also known as PERK), located on chromosome 2p11.2, which encodes a kinase involved in regulating protein translation in the endoplasmic reticulum. WRS is considered the most common cause of permanent neonatal diabetes in consanguineous families. The hallmark features of Wolcott-Rallison syndrome include permanent neonatal or early-infantile insulin-dependent diabetes mellitus, spondyloepiphyseal dysplasia (a skeletal abnormality affecting the vertebrae and long bone epiphyses), and recurrent episodes of acute liver failure. Additional features may include intellectual disability or developmental delay, renal dysfunction, exocrine pancreatic insufficiency, hypothyroidism, neutropenia, and recurrent infections. The skeletal dysplasia may not be apparent at birth but typically becomes evident in early childhood through short stature and radiographic changes. There is currently no cure for Wolcott-Rallison syndrome. Treatment is supportive and multidisciplinary, focusing on insulin therapy for diabetes management, monitoring and managing hepatic crises (which can be life-threatening), and addressing skeletal and other systemic complications as they arise. Episodes of acute liver failure may be triggered by intercurrent illness and require urgent medical attention. The prognosis is variable but often guarded, with many affected individuals experiencing significant morbidity in childhood. Early diagnosis, close metabolic monitoring, and coordinated care involving endocrinology, hepatology, orthopedics, and genetics are essential for optimizing outcomes.

Common questions about Wolcott-Rallison syndrome